A detailed history of Childress Capital Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Childress Capital Advisors, LLC holds 5,967 shares of BMY stock, worth $338,925. This represents 0.08% of its overall portfolio holdings.

Number of Shares
5,967
Holding current value
$338,925
% of portfolio
0.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$39.66 - $51.75 $236,651 - $308,792
5,967 New
5,967 $308,000
Q1 2024

Apr 24, 2024

BUY
$47.98 - $54.4 $224,498 - $254,537
4,679 New
4,679 $253,000
Q3 2023

Nov 06, 2023

BUY
$57.89 - $64.73 $278,103 - $310,962
4,804 New
4,804 $278,000
Q4 2022

Feb 03, 2023

BUY
$68.48 - $81.09 $24,995 - $29,597
365 Added 4.65%
8,210 $590,000
Q3 2022

Nov 03, 2022

SELL
$0.13 - $76.84 $115 - $68,080
-886 Reduced 10.15%
7,845 $567,000
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $26,651 - $29,352
367 Added 4.39%
8,731 $672,000
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $112,692 - $135,128
1,833 Added 28.07%
8,364 $612,000
Q4 2021

Jan 26, 2022

SELL
$53.63 - $62.52 $72,454 - $84,464
-1,351 Reduced 17.14%
6,531 $407,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $86,447 - $101,261
1,461 Added 22.75%
7,882 $465,000
Q2 2021

Jul 28, 2021

SELL
$61.91 - $67.42 $97,446 - $106,119
-1,574 Reduced 19.69%
6,421 $429,000
Q1 2021

May 21, 2021

BUY
$59.34 - $66.74 $191,905 - $215,837
3,234 Added 67.93%
7,995 $504,000
Q4 2020

Mar 09, 2021

BUY
$57.74 - $65.43 $274,900 - $311,512
4,761 New
4,761 $297,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Childress Capital Advisors, LLC Portfolio

Follow Childress Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Childress Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Childress Capital Advisors, LLC with notifications on news.